Bayer's Balance Sheet Gets a €2 Billion Cushion While Missouri Weighs the Roundup Reckoning

Bayer priced two €1 billion 30-year hybrid notes at 5.75% and 6.25%, lifting hybrid capital to €6.55 billion as it awaits a Missouri court ruling on its $7.25 billion Roundup settlement.

Bayer has turned to the hybrid bond market for the second time in its refinancing campaign, raising €2 billion on Wednesday through a pair of subordinated notes that institutional investors snapped up several times over. The two tranches, each sized at €1 billion with a 30-year tenor, carry coupons of 5.75% and 6.25% respectively — the lower rate attached to a six-year non-call period, the higher one to a nine-year lock-in. Bayer's earliest ordinary redemption option on the first tranche therefore falls no sooner than 2032.

Proceeds are earmarked for general corporate purposes, though the timing tells its own story. The issue slots into a broader push to shore up the group's capital structure ahead of a legal milestone that has loomed over the equity story for years.

Rating Agencies Treat Half the Issue as Equity

What makes hybrid paper attractive to a leveraged issuer is its treatment by the ratings agencies. Because the new obligations rank behind Bayer's other financial debt, S&P, Moody's and Fitch credit half the placed volume as economic equity. That accounting treatment lifts Bayer's total outstanding hybrid capital from €4.55 billion to €6.55 billion.

The pricing also marks a visible easing of conditions. For comparable instruments with shorter non-call periods, management had to offer coupons of 6.625% and 7.0% back in 2023. Securing cheaper funding despite the long tenors hands the Leverkusen-based group more balance-sheet breathing room.

A Funding Jigsaw Assembled Piece by Piece

The hybrid notes are only one tile in a mosaic of measures assembled over recent months. In July, financial investor Apollo injected €3 billion, which likewise counts toward equity for accounting purposes. Regular bond issuance added $5 billion, and the divestment of the cancer drug Stivarga to pharmaceutical company Grünenthal is set to bring in as much as €375 million.

September brought a further capital solution, with Apollo Funds and KKR closing a €3 billion financing arrangement for Bayer's long-acting reversible contraceptive business. Bayer retains operational control and a majority stake in the newly formed unit. On the operational front, the company has also notched wins: the FDA granted accelerated approval in early September for Sevabertinib, a cancer drug indicated for first-line treatment of adults with HER2-mutant non-small cell lung cancer. In Crop Science, additional products including Vyconic and Intacta 5+ are being prepared to modernize the agricultural portfolio.

The Courtroom Is the Real Catalyst

All of this financial engineering ultimately points toward one event. The negotiated Roundup settlement, worth up to $7.25 billion — roughly €6.3 billion — awaits final confirmation from a court in the US state of Missouri. A hearing on the proposed deal took place in mid-September, according to media reports, but no date has been set for a binding ruling.

Should the judge sign off without further conditions, the financial risk from the years-long litigation would be largely capped and covered by the resources already raised. That scenario would free the operating business to take center stage again, and the shares — up 35% since the start of the year — could extend their recovery, giving strategic future platforms such as cell and gene therapies more weight in the market valuation.

The opposite outcome carries real weight. As long as the Missouri court deliberates, the threat of amendments or procedural delays hangs over the company. If approval fails, or if the $7.25 billion proves insufficient to fend off future claims, another financial burden looms. And even in the best case, the interest obligations on the fresh €2 billion absorb substantial resources for years; should the hoped-for clean break in the US fail to materialize, those coupon payments would weigh on the balance sheet without delivering the valuation discount they were meant to dissolve.

Bayer shares added 0.9% on Wednesday to close at €49.92, building on a year-to-date advance of 34% that left the stock at €49.50 at the previous session's close. For investors, the decisive impulse will not come from the earnings report but from the bench: the pending judicial decision on the glyphosate settlement is the central milestone against which the current capital strategy must be measured.